Conjugation of cell-penetrating peptides with poly(Lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery by Vasconcelos, Aimee C. et al.
© 2015 Vasconcelos et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
International Journal of Nanomedicine 2015:10 609–631
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
609
O r I g I N a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/IJN.S71198
conjugation of cell-penetrating peptides with 
poly(lactic-co-glycolic acid)-polyethylene glycol 
nanoparticles improves ocular drug delivery
aimee Vasconcelos1
estefania Vega2
Yolanda Pérez3
María J gómara1
María luisa garcía2
Isabel haro1
1Unit of synthesis and Biomedical 
applications of Peptides, Department 
of Biomedical chemistry, Institute 
for advanced chemistry of 
catalonia, consejo superior de 
Investigaciones científicas (IQac-
csIc), 2Department of Physical 
chemistry, Institute of Nanoscience 
and Nanotechnology, Faculty of 
Pharmacy, University of Barcelona, 
3Nuclear Magnetic resonance Unit, 
IQac-csIc, Barcelona, spain
Abstract: In this work, a peptide for ocular delivery (POD) and human immunodeﬁciency 
virus transactivator were conjugated with biodegradable poly(lactic-co-glycolic acid) (PGLA)–
polyethylene glycol (PEG)-nanoparticles (NPs) in an attempt to improve ocular drug bioavail-
ability. The NPs were prepared by the solvent displacement method following two different 
pathways. One involved preparation of PLGA NPs followed by PEG and peptide conjugation 
(PLGA-NPs-PEG-peptide); the other involved self-assembly of PLGA-PEG and the PLGA-PEG-
peptide copolymer followed by NP formulation. The conjugation of the PEG and the peptide 
was conﬁrmed by a colorimetric test and proton nuclear magnetic resonance spectroscopy. Flur-
biprofen was used as an example of an anti-inflammatory drug. The physicochemical properties 
of the resulting NPs (morphology, in vitro release, cell viability, and ocular tolerance) were 
studied. In vivo anti-inflammatory efﬁcacy was assessed in rabbit eyes after topical instillation 
of sodium arachidonate. Of the formulations developed, the PLGA-PEG-POD NPs were the 
smaller particles and exhibited greater entrapment efﬁciency and more sustained release. The 
positive charge on the surface of these NPs, due to the conjugation with the positively charged 
peptide, facilitated penetration into the corneal epithelium, resulting in more effective preven-
tion of ocular inflammation. The in vitro toxicity of the NPs developed was very low; no ocular 
irritation in vitro (hen’s egg test–chorioallantoic membrane assay) or in vivo (Draize test) was 
detected. Taken together, these data demonstrate that PLGA-PEG-POD NPs are promising 
vehicles for ocular drug delivery.
Keywords: peptide for ocular delivery, flurbiprofen, controlled release, ocular tolerance, anti-
inflammatory
Introduction
Cataract is one of the most common causes of partial loss of vision, with an estimated 
16 million people affected worldwide. Surgical intervention is still the standard cataract 
treatment. Flurbiprofen (FB) is a nonsteroidal anti-inflammatory drug (NSAID), 
which has been introduced into ocular therapy recently, not only for the management 
of inflammatory diseases that affect ocular structures, but also for use during eye 
surgery.1 NSAIDs are widely used topically to inhibit intraoperative miosis, reduce 
postoperative inflammation, treat seasonal allergic conjunctivitis, and both prevent 
and treat cystoid macular edema.2 They have also recently been found to be useful in 
decreasing bacterial colonization of contact lenses and preventing bacterial adhesion 
to human corneal epithelial cells.3
The bioavailability of ophthalmic drugs in aqueous solutions is usually low due to 
their rapid elimination after mucosal instillation, a consequence of reflex blinking and 
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tear drainage, as well as of the presence of the corneal barrier. 
In fact, only 5% of the applied dose reaches intraocular tis-
sues after corneal penetration.4 Research into biomaterials 
has therefore included the use of biodegradable polymeric 
nanoparticles (NPs) in ocular drug delivery, one of the most 
promising applications of NPs, as they offer a controlled 
release proﬁle of a drug which is entrapped in the polymeric 
matrix .5–7 These are advantages that suggest that the required 
therapeutic effects could easily be achieved.8 Over the years, 
the potential of a variety of synthetic biodegradable poly-
mers such as polylactic acid, polyglycolic acid, and their 
copolymer, poly(lactic-co-glycolic acid) (PLGA), for the 
production of NPs, has been extensively explored due to their 
biocompatibility, biodegradability, and mechanical strength.9 
It has been described that PLGA NPs are internalized in 
cells partly through fluid phase pinocytosis and also through 
clathrin-mediated endocytosis, and they rapidly escape the 
endolysosomes and enter the cytoplasm. The reticuloen-
dothelial system eliminates the NPs from the blood stream. 
Subsequent PLGA hydrolysis leads to metabolite monomers 
(lactic and glycolic acids), which are easily metabolized via 
the Krebs cycle.10
Furthermore, they are easily formulated via several 
production methods such as solvent displacement,11 solvent 
diffusion, emulsiﬁcation–evaporation, and phase-inversion 
procedures.12,13 These polymers, which are commercially 
available in a range of molecular weights and copolymer 
ratios,14,15 have been approved by the US Food and Drug 
Administration and the European Medicine Agency for use 
in drug delivery in humans.16
FB has previously been formulated in PLGA NPs by 
Vega et al17 who achieved good stability and appropriate 
physicochemical properties for ocular administration, without 
causing ocular irritation at any level. Recently, other authors 
have reported that by means of a suitable modiﬁcation of the 
PLGA NPs, the stability of the encapsulated drug, its release 
proﬁle, and delivery to a speciﬁc target can be optimized.18–20 
PLGA has thus been combined with hydrophilic polymers 
such as polyethylene glycol (PEG) and polyethylene oxide. 
The modiﬁcation of preformed NPs with PEG (ie, PEGyla-
tion) brings about substantial changes in their physicochemi-
cal properties.21 PEG is a hydrophilic, nonionic polymer that 
has been shown to be highly biocompatible, and it can be 
added to NPs via a great number of different routes including 
covalent binding, mixing during NP preparation, and surface 
adsorption. The presence of PEG on the surface of NPs may 
provide other advantages, such as increasing their systemic 
circulation half-life and mucoadhesion.22
Furthermore, cell-penetrating peptides (CPPs) can be 
conjugated with NPs to enhance the cellular and nuclear 
uptake of the cargo molecules. CPPs are short (20 amino 
acids) cationic peptide sequences from a range of proteins 
that are capable of transporting molecules across the cell 
membrane. Despite the lack of a clear understanding of their 
mechanism of action, it has been demonstrated that CPPs 
can deliver different cargoes into cells, including peptides, 
proteins, viral particles, liposomes, and NPs.23,24 The most 
extensively studied CPPs are the human immunodeﬁciency 
virus transactivator protein (HIV-Tat),25 the herpes simplex 
virus type 1 protein VP2226 and the homeodomain transcrip-
tion factor Antennapedia.27 Several authors have studied the 
potential use of HIV-Tat28 and herpes simplex virus-VP2229 
in delivering recombinant proteins to human embryonic 
retinoblast in culture and to retinal tissues in vivo. It has been 
observed that while both peptides act efﬁciently in vitro, their 
performance in the retina in vivo is limited. Recently, a novel 
CPP for ocular delivery was reported (peptide for ocular 
delivery [POD]), that is capable of transporting both small 
and large molecules across the plasma membrane. Moreover, 
it enters the corneal epithelium, sclera, choroid, and the dura 
of the optic nerve via topical application. POD, is useful in 
a vehicle that targets ocular tissues and has bacteriostatic 
properties.30,31 Furthermore, the cornea possesses negative 
surface charges, and it is expected that cationic colloidal 
NPs may penetrate through the negatively charged ocular 
tissues more efﬁciently than anionic carriers.32 Read et al 
also demonstrated that PEGylated CPPs such as PEG-POD 
are promising candidates for gene delivery.33 The addition 
of a PEG moiety to the POD resulted in small, discrete, 
and spherical NPs, without any aggregation being observed 
in vitro. Moreover, they studied the gene transfer efﬁciency, 
with POD being more efﬁcient for subretinal DNA delivery 
than two other CPPs: HIV-Tat 28 and CK30.34 Particularly, 
PEG-POD DNA NPs have been utilized to deliver a plasmid 
expressing various marker genes or glial cell line-derived 
neurotrophic factor to mice, enabling rescue of photoreceptor 
degeneration. Thus, PEG-POD NPs have been considered a 
therapeutically relevant nonviral DNA vehicle with potential 
application in therapy for retinal degeneration.35,36
The main aim of the current study is to improve the cor-
neal epithelium penetration of NPs composed of PLGA-PEG 
by means of conjugating two different CPPs (POD and HIV-
Tat), the ﬁnal objective being to achieve a longer sustained 
release of FB, which has been used as an example of NSAID 
drug. Peptide-derivatized NPs were obtained by the solvent 
displacement method. Their physicochemical properties, 
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in vitro release kinetics, ex vivo interaction with corneal 
permeation, cytotoxicity, and ocular tolerance (in vitro and 
in vivo) were studied. Anti-inflammatory efﬁcacy assays 
were also performed to determine whether these novel formu-
lations (PLGA-NPs-PEG-peptide and PLGA-PEG-peptide 
NPs) could form the basis of a suitable strategy for ocular 
delivery of NSAIDs.
Materials and methods
Materials
PLGA with a 50:50 monomer ratio (Resomer® RG 503H, 
34 kDa, viscosity 0.32–0.44 dL/g) together with the PLGA 
50:50 and PEG copolymer (Resomer® RGP type d5055 
[PLGA-PEG®]) were purchased from Boehringer Ingelheim 
(Ingelheim, Germany). Maleimide-PEG-NH
2
 (2,000 Da) 
was obtained from Jenkem (Beijing, People’s Republic 
of China). Methoxy-PEG-NH
2
, N-hydroxysuccinimide 
(NHS), ethyl-3-(3-dimethylaminopropyl) carbodiimidey-
drochloride (EDC), N-diisopropylethylamine (DIEA), 
N-diisopropylcarbodiimide, 2-(1H-7-azabenzotriazol-1-yl)-
1.1.3.3-tetramethyluroniumhexafluorophosphate (HATU), 
1-hydroxybenzotriazole, and FB were purchased from Sigma 
(St Louis, MO, USA). Amino acids and NovaSyn TGR resin 
were purchased from Novabiochem (Hohenbrunn, Germany). 
N,N-Dimethylformamide (DMF) was obtained from Schar-
lau (Barcelona, Spain). Poloxamer 188 (Lutrol® F68) was 
from BASF (Barcelona, Spain) and 5(6)-carboxytetrameth-
ylrhodamine (Rho) was obtained from Merck (Hohenbrunn, 
Germany). Double-distilled water was used after ﬁltration in 
a Millipore system. All other chemicals and reagents used in 
the study were of analytical grade.
Peptide synthesis
The POD (CGGG[ARKKAAKA]
4
)  and HIV-Tat 
(CGGGGYGRKKRRQRRR) peptides were synthesized in 
the solid phase using fluorenylmethoxycarbonyl protected 
amino acids following procedures previously described.37,38 
The polyglycine sequence is an adequate spacer while the 
N-terminal cysteine reacts with maleimide-activated PEG. 
Carboxamide peptides were obtained using NovaSyn TGR 
resin (0.25 eq/g). HATU was used as a coupling reagent in 
DMF activated with DIEA.
All the synthesized peptides were characterized by 
reversed-phase high-performance liquid chromatography 
(RP-HPLC). The RP-HPLC system consisted of an Agilent 
1260 pump (Quat Pump VL) with a UV-Vis 1260 ALS 
detector set at 215 nm. A reversed-phase column (Kromasil 
C18 25×0.46 cm and 5 µM mean particle size) with a flow 
rate of 1 mL/min was used. Matrix-assisted laser desorption/
ionization-time of flight (MALDI-TOF) mass spectrometry 
was used to determine the molecular weight. 2.5-Dihydroxy-
benzoic acid was used as the matrix, and the peptides were 
dissolved in acetonitrile (ACN)/water 30% v/v with 0.01% 
v/v trifluoroacetic acid at a concentration of 1 mg/mL. The 
sample was run in an AutoFlex III Smart Bean Bruker mass 
spectrometer, operating in reflector mode, and positive ions 
were monitored. A nitrogen laser beam at 200 nm was used, 
and 500 shots were averaged for each spectrum. The crude 
peptides were puriﬁed by semipreparative HPLC, yielding 
a purity of more than 95%.
Preparation of NPs
general procedure
NPs containing FB were prepared by the solvent displace-
ment technique described by Fessi et al11 under the optimized 
conditions determined previously.17,39–41 Briefly, an organic 
solution of 90 mg of polymer PLGA 503H in 5 mL of acetone 
containing FB (10 mg) was poured, under moderate stir-
ring, into 10 mL of an aqueous solution, adjusted to pH 3.5, 
containing 100 mg of Lutrol® F68. The resulting colloidal 
suspension was stirred for 5 minutes. The acetone was then 
evaporated, and the NP dispersion volume was concentrated 
under reduced pressure. Empty NPs were prepared using the 
same procedure but without FB being added to the organic 
phase.
The NPs were obtained by two different routes: one 
involving the preparation of PLGA NPs followed by PEG 
and peptide conjugation; and the other involving the self-
assembly of PLGA-PEG and the PLGA-PEG-peptide 
copolymer followed by NP formulation (Figure 1).
synthesis of Pegylated-Plga NPs and peptide 
conjugation: Plga-NPs-Peg-peptide
PLGA NPs in suspension were incubated with 2.4 mg 
(21 µmol) of NHS, and then 4.1 mg (21 µmol) of EDC 
was added. The pH was adjusted to 3.5, and the mixture 
was incubated for 6 hours at room temperature with gentle 
stirring. The resulting PLGA-NHS-activated particles were 
covalently linked to 5.2 mg (2.6 µmol) NH
2
-PEG-maleimide. 
Next, PLGA-PEG NPs were covalently linked to 2.6 µmol 
of POD (9.4 mg) or HIV-Tat (5 mg) peptides. The reac-
tion procedure is shown in Figure 1A. The presence of the 
peptides was conﬁrmed by MALDI-TOF mass spectrometry 
under the same conditions as explained above. Finally, the 
unreacted PEG and peptide was separated from the NPs by 
centrifugation at 14,000 rpm and 4°C for 30 minutes.
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The free PEG was quantiﬁed via a 2,4,6-trinitrobenze-
nesulphonic acid (TNBS) assay.42,43 In separate test tubes, 
100 µL of aqueous solution containing free PEG or borate 
buffer was prepared (pH 8.0 for the blank) by mixing 900 µL 
of 0.1 M borate buffer (pH 9.3) and 40 µL of 0.03 M TNBS. 
The solution was incubated at room temperature for 
30 minutes, and the absorption at 420 nm was determined 
spectrophotometrically. The amount of conjugated PEG was 
calculated by subtracting the amount of free PEG from the 
total amount added.
Unreacted POD and HIV-Tat were quantified using 
Ellman’s assay.44 A solution of 0.1–0.2 µmol of the peptides 
in sodium phosphate buffer was prepared and then 100 µL 
of DTNB (5.5 dithiobis[2-nitrobenzoic acid]) was added to 
the peptide solution, and the mixture was left to stand for 
15 minutes. DTNB and the buffer were used as reference 
solutions. Absorbance was determined spectrophotometri-
cally at 410 nm. The concentration of sulfhydryl groups, and 
thus of the corresponding free peptide, was calculated using 
the following equation:
 SH = (A
410
 [sample] - A
410
 [reference])/13,650 (1)
synthesis of Plga-Peg and Plga-Peg-peptide
As shown in Figure 1B, PLGA was preactivated before PEGy-
lation with maleimide-PEG-amine. One gram (32.3 µmol) 
of PLGA, with an inherent viscosity of 0.32–0.44 dL/g was 
dissolved in 2 mL of chloroform with stirring in a tightly 
sealed vial. Then, 45 mg (234.7 µmol) of EDC and 27 mg 
(234.7 µmol) of NHS was added, and the mixture was 
stirred overnight in a tightly sealed vial. The preactivated 
PLGA-NHS was precipitated with 8 mL of diethyl ether and 
centrifuged at 4,000 rpm for 10 minutes at room temperature. 
Following centrifugation, the supernatant was discarded 
and the polymer redissolved in 2 mL of chloroform. This 
precipitation/dissolution washing cycle was repeated three 
times before the activated PLGA-NHS ester was dried under 
vacuum and stored at -20°C. Then, 500 mg (16.2 µmol) of 
PLGA-NHS was dissolved in 2 mL of chloroform, and once 
it was fully dissolved, 35 mg (17.5 µmol) of maleimide-PEG-
amine or metoxi-PEG-amine (nontargeted particles) and 
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Figure 1 synthesis of (A) Plga-NPs-Peg-peptide and (B) Plga-Peg-peptide polymer followed NPs preparation.
Abbreviations: EDC, ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride; FB, flurbiprofen; NHS, N-hydroxysuccinimide; NPs, nanoparticles; PEG, polyethyleneglycol; 
Plga, poly(lactic-co-glycolic acid); sh, sulfhydryl group.
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20 µL (117.15 µmol) of DIEA was added, the vial was tightly 
sealed, and the mixture was stirred overnight. The product 
was precipitated with 8 mL of an ice-cold 80/20 mixture 
of diethyl ether/methanol and centrifuged at 4,000 rpm for 
10 minutes. After the supernatant was discarded, the product 
was redissolved in 2 mL of chloroform, and the washing cycle 
was repeated twice more. The PLGA-PEG copolymer was 
dried under vacuum and stored at 4°C. The percentage yield 
was calculated as follows:
[weight of  PLGA PEG]
Yield (%) 100
[weight of  PLGA NHS and PEG-amine] 
−= ×
−
 (2)
To conjugate the peptides with the PLGA-PEG-maleimide, 
2.7 µmol of POD (9.8 mg) or HIV-Tat (5.2 mg) was dissolved 
in 250 µL of ACN/DMF and added to 100 mg (2.7 µmol) of 
the polymer dissolved in 1 mL of chloroform. The mixture 
was covered tightly and stirred overnight. The product was 
precipitated with 3 mL of an ice-cold 80/20 mixture of diethyl 
ether/methanol, centrifuged at 4,000 rpm for 10 minutes, the 
supernatant discarded, and the product redissolved in 1 mL of 
chloroform. This cycle was repeated twice more, and then the 
PLGA-PEG-peptide was dried under vacuum.
Proton nuclear magnetic resonance (1H-NMR) was used 
to assess the grafting of PEG to PLGA and the conjugation 
with the peptide. The PLGA-PEG was dissolved in deuterated 
chloroform and the PLGA-PEG-peptide in dimethyl sulfoxide 
(DMSO)-d
6
. The spectrum was recorded at 298 K on a Varian 
Inova 500 MHz spectrometer (Agilent Technologies, Santa 
Clara, CA, USA). Then, PLGA-PEG NPs and PLGA-PEG-
peptide NPs containing FB were prepared following the 
general procedure described above.
characterization of NPs
Particle size, polydispersity index, and zeta potential
The mean particle size, polydispersity index, and zeta poten-
tial (Z
pot
) were determined via dynamic light scattering using 
a Zetasizer nano ZS (Malvern Instruments, Malvern, UK) 
at 25°C. The measurements were performed on samples 
previously diluted in Milli-Q® water (Millipore Corporation, 
Billerica, MA, USA). Z
pot
 is a measure of the electric charge 
at the surface of NPs, an indirect measure of their physical 
stability. Z
pot
 values were calculated by determining the 
electrophoretic mobility using the Helmholtz–Smoluchowski 
equation, as previously reported.39 The values we report are 
the mean ± standard deviation (SD) of at least three different 
batches of each NP formulation.
Entrapment efficiency
The nonentrapped FB was separated by filtration/
centrifugation using Amicon centrifugal ﬁlter devices with 
100 kDa Ultracel membrane (Millipore Corporation) at 
3,000 rpm for 10 minutes (Digicen 20-R centrifuge, Madrid, 
Spain). The samples were diluted (1:10) before injection with 
Milli-Q water to avoid deposition of free FB on the NPs. 
The concentration of FB in the supernatant was measured by 
RP-HPLC. The mobile phase was composed of ACN/water 
(65:35) acidiﬁed with phosphoric acid (pH 2.5). The column 
effluent was examined spectrophotometrically at 254 nm and 
the flow rate was set at 1 mL/min. The retention time of FB 
was 11.8 minutes. The calibration curve was linear in the 
range 0.0014–0.75 mg/mL with a correlation coefﬁcient, r2, 
of 0.999. The percentage FB entrapment efﬁciency (EE) was 
calculated as indicated below:
 
[total amount of FB free FB] 
EE (%) 100
[total amount of FB]
−= ×  (3)
Morphological studies
The morphology of the NPs was studied by scanning electron 
microscopy (SEM). The NPs were centrifuged at 14,000 rpm 
at 4°C for 30 minutes. The supernatant was discarded and the 
pellet was dried under vacuum. Samples were attached to a 
metal stub, sputter coated with chrome, and viewed under 
Hitachi S43000 SEM apparatus.
In vitro drug release
In vitro release studies of FB from the NPs were carried out 
by applying the bulk equilibrium dialysis bag technique.45 The 
experiments were performed under ‘‘sink conditions’’ in order 
to avoid interference of FB solubility in the in vitro release. 
An NP formulation containing 1 mg/mL of FB, a control solu-
tion of FB (1 mg/mL), and 0.3 mg/mL commercial eye drops 
(Ocufen®) were placed into dialysis sacs (cellulose membrane 
with a molecular weight cut-off of 12,000 Da [Iberlabo, Madrid, 
Spain]) into 150 mL of phosphate buffered saline (PBS) 
(0.1 M, pH 7.4). The dialysis sacs were previously equilibrated 
in PBS. The temperature was maintained at 32°C (surface eye 
temperature) with moderate, continuous stirring. At speciﬁc 
time intervals, 1 mL was taken from the release medium and 
immediately replaced with 1 mL of fresh PBS. The concen-
tration of the drug released was assessed as described above. 
Values are reported as the mean ± SD of three replicates.
Data obtained from in vitro release studies were ﬁtted to 
the Korsmeyer–Peppas equation to determine the mechanism 
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of drug release from the NPs.46 The Korsmeyer–Peppas 
model is,
 M
t
/M∞ = k ⋅ tn (4)
where M
t
 is the amount of drug released at time t, M∞ is 
the total amount released, M
t
/M∞ is the fraction of drug 
released at time t, k is the release rate constant, and n is 
the diffusion exponent that indicates the mechanism of 
drug release. Several mechanisms may be involved in 
the release process from spherical matrices: drug dif-
fusion from NPs (or the Fickian mechanism; n0.43), 
non-Fickian transport (or case-II transport, zero order; 
n0.85) or a combination of both processes (anoma-
lous transport; 0.43n0.85). In order to ﬁt only the 
Korsmeyer–Peppas empirical model, an initial 60% of 
drug released was used.
Fluorescence studies to visualize the NPs
synthesis of Plga-Peg-peptide-rho
To evaluate the interaction of the PLGA-PEG-peptide NPs 
with the corneal epithelium, the peptides were prelabeled 
with Rho. A volume of 50 mg of peptidyl resin (contain-
ing POD or HIV-Tat) was added to 12.9 mg of Rho. The 
reaction was carried out using N-diisopropylcarbodiimide 
and 1-hydroxybenzotriazole in DMF medium for 24 hours 
in the dark. MALDI-TOF mass spectrometry was used to 
determine the molecular weight of the Rho-peptide. The 
degree of labeling was calculated separately by determining 
the peptide and Rho molar concentrations of the conjugate 
based on absorbance measurements; these concentrations 
were then expressed as a ratio (Rho:peptide molar ratio). 
Then, unlabeled peptides (2 mg [0.6 µmol]) POD or 1 mg 
[0.6 µmol] HIV-Tat) and the labeled Rho-peptides (0.9 mg 
[0.25 µmol]) Rho-POD or 0.4 mg [0.22 µmol] Rho-HIV-
Tat) were conjugated with 30 mg (0.84 µmol) of polymer 
PLGA-PEG-maleimide, as detailed above. The new NPs not 
containing FB were prepared using the solvent displacement 
method as described above. The amount of Rho-peptides 
in the NPs was determined by fluorescence spectroscopy 
(excitation at 555 nm and emission at 580 nm). Standard 
curves were obtained by diluting Rho with blank PLGA-
PEG NPs in the concentration range 0.1–1 µM. The PLGA-
PEG-peptide-Rho NPs were analyzed by fluorescence 
microscopy. The particles were excited with a 572 nm laser 
and emissions registered between 570 and 590 nm. This 
channel was depicted as green to facilitate visualization 
on the computer screen.
ex vivo study by confocal laser scanning 
microscopy
In these studies, New Zealand white rabbits with no signs 
of abnormalities or ocular inflammation and weighing 
1.8–2.2 kg were used. All experiments were performed 
according to the ARVO (Association for Research in 
Vision and Ophthalmology) resolution for the use of 
animals in research and the corresponding protocols were 
approved by the ethics committee for animal experimenta-
tion of the University of Barcelona. Volumes of 50 µL of 
each formulation were administered into the conjunctival 
sac of the rabbit. After 2 hours of instillation, the rabbits 
were killed. A corneal specimen, freshly extracted, was 
directly mounted on a glass slide, and both the membrane 
dye wheat germ agglutinin and the nucleus dye 2,5′-bi-
1H-benzimidazole, 2′-(4-ethoxyphenyl)-5-(4-methyl-1-
piperazinyl) (Hoechst) were added. Images were taken 
using confocal laser scanning microscopy (CLSM) with 
a Leika TCS SP2 AOTF laser, 40×/1.25 oil objective and 
background fluorescence were registered by laser excitation 
at 364, 488, and 561 nm.
cytotoxicity assays
The cytotoxicity of the NPs was evaluated using a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay. 
HeLa and HepG2 cells were cultured in Dulbecco’s Modi-
ﬁed Eagle’s Medium (D5796; Sigma) supplemented with 
10% heat-inactivated fetal bovine serum (Invitrogen) and 1% 
penicillin-streptomycin (P11-010; PAA) under 5% CO
2
 at 
37°C. The HeLa and HepG2 cells were cultured in 96-well 
plates by adding 100 µL of a suspension of 100,000 cells/mL 
(total density of 10,000 cells/well) and incubated for 24 hours 
to allow cell attachment. The medium was then replaced with 
150 µL of medium containing FB-loaded PLGA-PEG-POD 
NPs and PLGA-PEG-HIV-Tat NPs at different concentrations 
(0.01–25 mg/mL) and incubated for 24 hours in triplicate. Then, 
the culture medium was removed from the wells to avoid inter-
ference and replaced with 100 µL of MTT (5 mg/mL in PBS was 
prepared and diluted 1:5 with fresh medium). The plates were 
again incubated for 3 hours under the same conditions. After 
this time, the medium was aspirated and replaced by 100 µL 
of DMSO to dissolve the crystals formed in the previous step 
and then incubated for 2 hours at room temperature in the dark. 
Finally, absorbance was measured spectrophotometrically at 
570 nm using a SpectraMax M5 spectrophotometer (Molecular 
Devices, Sunnyvale, CA, USA). Untreated cells were used as a 
control with 100% viability. The results were processed using 
GraphPad Prism 5 software.
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Ocular tolerance assays
In vitro heT-caM
The risk of ocular irritation by the NPs was assessed using the 
hen’s egg test–chorioallantoic membrane (HET-CAM) assay.47 
Hen’s eggs were incubated for 9 days and after this time defec-
tive eggs were discarded. The shell around the air cell was 
removed and the inner membranes extracted to reveal the 
CAM. NPs were added to the membrane and left in contact 
for 5 minutes. After proceeding with the positive control, one 
egg was treated with 0.1 M sodium hydroxide and six eggs 
were used for each sample tested. After exposing the CAM and 
rinsing it with PBS, 300 µL of the test solution was applied to 
the CAM. The intensity of the reactions was semiquantitatively 
assessed on a scale from 0 (no reaction) to 3 (strong reaction). 
The time of onset and intensity of reactions occurring within 5 
minutes were recorded. The ocular irritation index (OII) was 
then calculated using the following expression:
 OII =  (301 - h) × 5/300 + (301 - l) 
× 7/300 + (301 - c) × 9/300
 (5)
where h is the time (in seconds) to the beginning of hemor-
rhage, l time to lysis, and c time to coagulation. The following 
classiﬁcation was used: OII 0.9, slightly irritating; 0.9 
OII 4.9, moderately irritating; 4.9 OII 8.9, irritating; 
and 8.9 OII 21, severely irritating.
In vivo Draize test
An In vivo Draize test was performed to conﬁrm the results 
obtained by the HET-CAM assay. The study was conducted 
using a modiﬁed Draize test.48 The irritation associated with 
the instillation of hypotonic and hypertonic suspensions may 
lead to reflex tearing or reflex blinking. The osmolality of the 
samples, measured with a Fiske osmometer, was adjusted with 
5% (w/v) glucose to the tear osmolality (around 280 mOsm/
kg).49 In order to avoid these effects in the ocular assays, the 
formulations tested were adjusted to tear fluid (pH 7.4) using 0.1 
N sodium hydroxide. A single instillation of 50 µL of each NP 
was applied to one eye of the New Zealand white rabbits, and 
the other eye was used as a control. After 1 hour of exposure, 
the eyes were observed to evaluate possible injury to the cornea, 
conjunctiva, or iris, and subsequent readings were taken after 1, 
2, 3, 4, and 7 days. The Draize score was determined by visual 
assessment of changes in the ocular structure involving cornea 
(turbidity or opacity), iris (inflammation degree), and conjunc-
tiva (congestion, swelling, and discharge). Ocular lesions were 
quantiﬁed using the mean total score (MTS) equation:
 MTS = Σ X1(n) × 5 + Σ X2(n) × 2 + Σ X3(n) × 5 (6)
where X1(n), X2(n), and X3(n) are the cornea, conjunctiva, 
and iris scores, respectively, and n is the number of rabbits 
included in the ocular tolerance assay. Three animals were 
used for each formulation.
Anti-inflammatory efficacy assay
In order to study the prevention and treatment of ocular 
inflammation in cataract surgery by NPs, inflammation was 
induced by topical administration of sodium arachidonate 
(SA) (0.5% w/v) dissolved in PBS (pH 7.4). Following the 
experimental procedure described by Spampinato et al50 SA 
was inoculated in the right eye of ﬁve groups of six rabbits 
while the left eye was used as a control. The osmolarity 
and pH of each formulation were adjusted. The treatment 
protocol consisted of the induction of ocular inflamma-
tion by SA, and after 30 minutes the instillation of 50 µL 
of each formulation. In order to evaluate the prevention 
of inflammation (prophylaxis) by the NPs, 50 µL of each 
sample was instilled in the conjunctival sac of the right eye 
30 minutes before induction of ocular inflammation by SA. 
Ocular inflammation was assessed from 60 minutes to 210 
minutes, and the ocular inflammation score was calculated 
using the MTS as described above. Corneal transparency is 
not affected by SA, so this parameter was not considered. 
The total score of the conjunctiva and iris are expressed as 
mean ± SD.
statistical analysis
All the data were presented as mean ± SD. Speciﬁc com-
parison between groups was carried out with an unpaired 
Student’s t-test (two tailed). For multiple-group comparison, 
one-way ANOVA was carried out to analyze the signiﬁcant 
differences (P0.05) between groups, followed by Tukey 
post hoc analysis after having conﬁrmed normality and equal 
variance assumptions by the Kolmogorov–Smirnov statistical 
test. SPSS IBM21 for Windows was used throughout.
Results and discussion
synthesis of POD and hIV-Tat
Two different CPPs (POD and HIV-Tat) containing cysteine 
at the N-terminus were synthesized using solid phase 
methods.51 The crude peptides were puriﬁed by semiprepara-
tive HPLC, yielding over 95% purity. The puriﬁed synthetic 
products were characterized by MALDI-TOF (Figure S1).
characterization of Plga-NPs-Peg-
peptide
As previously described by Vega et al17,39 and Araújo et al40 
PLGA NPs are promising systems for the delivery and 
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controlled release of FB in ocular tissues. In this work, 
considering the results previously published by our group, 
optimized PLGA NPs incorporating FB were obtained using 
the solvent displacement technique. Lutrol® F68 was chosen 
as a surfactant to stabilize the NPs in aqueous suspension 
since, due to its nonionic character, it does not strongly 
irritate ocular tissues. Furthermore, it is accepted for ocular 
administration by regulatory authorities.52
POD and HIV-Tat were conjugated with PLGA NPs using 
PEG as a spacer by means of a maleimide-thiol coupling 
reaction. MALDI-TOF mass spectroscopy conﬁrmed that 
the reactions went to completion. The mass spectra of the 
peptides (POD and HIV-Tat) as well as their conjugation 
with PLGA-PEG-maleimide NPs are shown in Figure S1. 
The molecular weights obtained correspond to a combina-
tion of PEG and POD (5,500–5,900 Da) or HIV-Tat (3,700–
4,400 Da). The peptides and PEG located on the surface were 
determined after each reaction step. These concentrations 
were determined indirectly by quantifying the amount of 
peptides remaining in solution. The conjugation efﬁciency 
was 2.5%, and the percentages of POD and HIV-Tat peptides 
were 1.2% and 2.1%, respectively.
characterization of Plga-Peg and 
Plga-Peg-peptide
PLGA-PEG (PEG, 2,000 Da) was synthesized with the pri-
mary aim of studying whether the form of presentation of 
PEG in PLGA-PEG® (PEG®, 5,000 Da) influences the NP 
properties in accordance with the different molecular weights. 
Furthermore, bifunctional PEG containing a maleimide group 
at one terminus and an amine group at the other was used to 
form PLGA-PEG-maleimide. With the aim of characterizing 
the synthetic PLGA-PEG, this copolymer was analyzed by 
1H-NMR spectroscopy. The 1H-NMR analysis revealed four 
characteristic peaks at 1.5 ppm (CH
3
 lactide proton), 3.6 
ppm (CH
2
-CH
2 
ethylene glycol protons), 4.8 ppm (CH
2
 gly-
colide proton), and 5.2 ppm (CH lactide proton) (Figure S2). 
A small peak was also observed at 6.7 ppm corresponding 
to the maleimide methine protons. These results conﬁrm the 
presence of both PLGA and PEG domains in the PLGA-PEG 
synthetic copolymer. We also used 1H-NMR to determine the 
resulting molar ratio of PLGA to PEG and of PEG to maleim-
ide by integration of the PLGA (CH
3
), PEG (CH
2
-CH
2
), and 
maleimide peaks, the conjugation efﬁciencies achieved being 
between 7%–15% and 2%–35% for PEG to PLGA and for 
maleimide to PEG, respectively. Then, POD and HIV-Tat 
were conjugated with the PLGA-PEG via cysteine/maleim-
ide linkage. The 1H-NMR spectra of PLGA-PEG-POD and 
PLGA-PEG-HIV-Tat are shown in Figure 2, conﬁrming the 
peptide coupling to PLGA-PEG-maleimide polymer. The 
amount of peptide (POD or HIV-Tat) in the polymer was 
expressed as a mass percentage, according to the following 
equation:53
 Peptide Peptide
Peptide
PLGA PLGA
100 (M  [I /n])
W
(M  [I  {CH, 5.2}])
=
δ=
 (7)
where M
Peptide 
and M
PLGA 
(130 g/mol) are, respectively, the 
molecular weight of the peptides and PLGA; I
PEPTIDE
 is the 
peak integral of POD (amide/amine region, 7.0–8.2 ppm) 
and HIV-Tat (tyrosine [Tyr] signal at 6.64 ppm); I
PLGA
 is the 
peak integral of the –CH groups in the polylactic acid unit 
of the PLGA corresponding to one proton; and n is number 
of protons (76 H for amide, amine, and guanidinium side 
chains in POD and 2 H for the isolated signal at 6.64 ppm 
corresponding to two aromatic protons of Tyr in HIV-Tat). 
Following this procedure, the calculated functionalization 
levels obtained were between 3.3%–3.9% and 2.3%–3.2% for 
PLGA-PEG-POD and PLGA-PEG-HIV-Tat, respectively.
Physicochemical characterization  
of FB-loaded NPs
For ocular administration drug delivery systems, particle size 
is an important parameter since it affects the risk of irritation 
and discomfort; certain sizes induce tearing and rapid drain-
age of the instilled dose thereby reducing the bioavailability 
and residence time of the drug in the conjunctival sac.54 In 
general, as shown in Tables 1 and 2, all the formulations we 
prepared had a suitable particle size for ocular administration 
(smaller than 250 nm diameter) and also the PI was lower 
than 0.1, indicating narrow particle size distributions.
The results of the physicochemical characterization of 
PLGA-NPs-PEG-POD and PLGA-NPs-PEG-HIV-Tat are 
shown in Table 1. The results show that the ﬁnal conjugations 
had slightly increased particle sizes, indicating that the attach-
ment of PEG and peptides to the surface of PLGA NPs took 
place (Figure 1A). In contrast, the size of PLGA-NPs-PEG-
POD and PLGA-NPs-PEG-HIV-Tat was similar, indicating 
that neither the choice of peptide nor the level of function-
alization of the NPs affected their size. Moreover, high EE 
was obtained (between 70.3%±5.6% and 76.5%±3.8%), 
indicating that PEG and peptide surface conjugation did not 
lead to a dramatic loss of the drug. Nonsigniﬁcant differ-
ences in the EE of FB were observed for PLGA-NPs-PEG-
HIV-Tat. The following P-values were obtained: 0.764 for 
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A Residual impurity
from polymer
sample
Residual
DMF
f1 (ppm)
8.5 8.4 8.3 8.2 8.1 8.0 7.9 7.8 7.7 7.6 7.5 7.4 7.3 7.2 7.1 7.0 6.9 6.8 6.7
Maleimide
free proton
PLGA-PEG-Mal-POD
Peptide POD
B
f1 (ppm)
7.25 7.20 7.15 7.10 7.05 7.00 6.95 6.90 6.85 6.80 6.75 6.70 6.65 6.60 6.55 6.50 6.45 6.40 6.35
Maleimide
free proton
2H Tyr 2H Tyr
PLGA-PEG-Mal
PLGA-PEG-Mal-TatHIV
Figure 2 The 1H-NMR spectra of PLGA-PEG-POD and PLGA-PEG-HIV-Tat confirm the peptide coupling to PLGA-PEG-maleimide polymer.
Notes: 1h-NMr spectra in DMsO-d6 at 25°c of (A) PLGA-PEG-maleimide-POD copolymer and POD peptide. We used the specified amide/amine side chain region for 
peptide signal integration. (B) For Plga-Peg-maleimide-hIV-Tat and Plga-Peg-maleimide, we clearly see a reduction of the maleimide methine protons signal intensity and 
the appearance of Tyr aromatic protons from hIV-Tat peptide after conjugation.
Abbreviations: 1h-NMr, proton nuclear magnetic resonance; DMF, N,N-Dimethylformamide; DMsO, dimethyl sulfoxide-d6; HIV-Tat, human immunodeficiency virus 
transactivator; Mal, maleimide; Peg, polyethyleneglycol; Plga, poly(lactic-co-glycolic acid); POD, peptide for ocular delivery; Tyr, tyrosine.
PLGA-NPs-PEG-HIV-Tat versus PLGA NPs and 0.473 for 
PLGA-NPs-PEG-HIV-Tat versus PLGA-NPs-PEG. Thus, 
no release of initial loaded FB took place during these reac-
tion steps. However, in the case of PLGA-NPs-PEG-POD, 
the EE of FB was up to 20% lower than that obtained for 
PLGA NPs (P=0.042). Table 2 shows the physicochemical 
properties of the PLGA-PEG-peptide NPs prepared from 
POD and HIV-Tat grafted onto the PLGA-PEG-maleimide 
copolymer, following the strategy illustrated in Figure 1B. 
The PLGA-PEG NPs obtained with the diblock copolymer 
that was synthesized in our laboratory were smaller than 
the NPs prepared from the commercial diblock copolymer 
(PLGA-PEG®). This may be due to the reduction of the 
molecular weight of the copolymer (PLGA segments).55,56 
However, PLGA-PEG-peptide NPs (with greater molecular 
weight than PLGA-PEG NPs due to the peptide conjugation) 
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were smaller in the case of PLGA-PEG-POD NPs than in 
the case of PLGA-PEG-HIV-Tat NPs. Finally, the PLGA-
PEG-peptide NPs exhibited signiﬁcantly higher EE values 
(81.0%±1.7%–82.9%±0.8%) than PLGA-PEG NPs (P=0.004 
and P=0.007 for POD and HIV-Tat, respectively). These 
results indicate that a slight drug association exists when the 
peptides are within the polymer matrix.
Some different characteristics were observed depending 
on the preparation method. In general, PLGA-PEG-peptide 
NPs were smaller and with relatively higher EE values than 
PLGA-NPs-PEG-peptide.
The Z
pot
 value is also an important NP physicochemical 
parameter, as it can influence the stability of the particles. 
In theory, larger magnitudes of Z
pot
 values, whether posi-
tive or negative, tend to stabilize particle suspension. The 
electrostatic repulsion between NPs with the same electric 
charge prevents their aggregation.57 Our Z
pot
 results show 
highly negative values for PLGA NPs and PLGA-PEG NPs 
due to the ionization of the carboxylic end groups of the 
polymer surface.58 Conjugation with positively charged POD 
or HIV-Tat changed the anionic Z
pot
 of the resultant NPs to 
cationic; this effect was higher for PLGA-NPs-PEG-peptides, 
whereas PLGA-PEG-peptide NPs had lower Z
pot
 values due to 
the presence of PEG and the peptides in the polymer matrix, 
which mask the PLGA charge. As previously reported, the 
presence of a positive charge is expected to promote ocular 
mucoadhesion due to electrostatic interactions with the 
negatively charged ocular mucosa.59
Morphology
The morphology of the NPs was determined by SEM (Figure S3). 
A spherical shape can be appreciated with a particle size of some 
120 nm and a narrow size distribution. SEM analysis conﬁrmed 
the dynamic light scattering data on NP size. Similar results were 
obtained for all the NPs involved in this study, indicating their 
suitability for ophthalmic applications.54
In vitro release profiles
Sustained release of FB over several hours might greatly 
improve its therapeutic efﬁcacy. The in vitro release behavior 
of FB from NPs containing POD and HIV-Tat, a solution of 
FB (1 mg/mL) in 0.1 M PBS (pH 7.4), and the commercial 
eye-drops Ocufen® were therefore analyzed. We used the 
dialysis bag diffusion technique (Figure 3). As expected, 
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Table 1 Physicochemical properties (with and without FB) and ee of Plga NPs, Plga-NPs-Peg, and Plga-NPs-Peg-peptide
NPs composition Size ± SD (nm) PI ± SD Zpot ± (mV) EE ± SD (%)
Plga 50:50 NPs 148.4±2.0 0.064±0.027 -29.1±1.3 –
Plga 50:50 NPs + FB 190.5±1.5 0.065±0.020 -30.4±3.3 77.1±4.2
Plga-NPs-Peg 164.5±1.8 0.079±0.018 -32.5±1.5 –
Plga-NPs-Peg + FB 170.3±3.5 0.084±0.014 -30.6±0.7 75.4±2.0
Plga-NPs-Peg-POD 203.8±1.4 0.060±0.009 33.2±1.7 –
Plga-NPs-Peg-POD + FB 219.9±1.2 0.082±0.010 30.2±1.4 70.3±5.6
Plga-NPs-Peg-hIV-Tat 218.4±0.9 0.075±0.045 25.2±2.6 –
Plga-NPs-Peg-hIV-Tat + FB 210.7±0.2 0.076±0.050 20.2±1.2 76.5±3.8
Notes: Values are expressed as mean ± sD; n=3.
Abbreviations: EE, entrapment efficiency; FB, flurbiprofen; HIV-Tat, human immunodeficiency virus transactivator; NPs, nanoparticles; PEG, polyethylene glycol; 
PI, polydispersity index; Plga, poly(lactic-co-glycolic acid); POD, peptide for ocular delivery; sD, standard deviation; Zpot, zeta potential.
Table 2 Physicochemical properties (with and without FB) and ee of Plga NPs, Plga-Peg NPs, Plga-Peg-peptide NPs
NPs composition MW (kDa) Size ± SD (nm) PI ± SD Zpot ± SD (mV) EE ± SD (%)
Plga-Peg NPs Plga (34) Peg (2) 105.1±0.2 0.080±0.026 -24.3±3.3 –
Plga-Peg NPs + FB 128.9±0.9 0.079±0.017 -12.6±3.0 73.3±3.3
Plga-Peg® NPs Plga (95) Peg (5) 147.7±1.1 0.095±0.039 -24.0±0.7 –
Plga-Peg® NPs + FB 150.8±1.0 0.096±0.017 -20.9±1.1 78.0±2.5
Plga-Peg-POD NPs Plga (34) Peg (2) POD (3.6) 85.9±0.9 0.011±0.020 15.2±0.3 –
Plga-Peg-POD NPs + FB 103.7±0.3 0.097±0.014 18.6±1.5 82.9±0.8
Plga-Peg-hIV-Tat NPs Plga (34) Peg (2) hIV-Tat (1.9) 102.8±1.1 0.012±0.010 20.0±0.4 –
Plga-Peg-hIV-Tat NPs + FB 123.1±1.7 0.103±0.007 14.0±0.8 81.0±1.7
Notes: Values are expressed as mean ± sD; n=3.
Abbreviations: EE, entrapment efficiency; FB, flurbiprofen; HIV-Tat, human immunodeficiency virus transactivator; NPs, nanoparticles; PEG, polyethylene glycol; 
Peg®, resomer® rgP type d5055; PI, polydispersity index; Plga, poly(lactic-co-glycolic acid); POD, peptide for ocular delivery; sD, standard deviation; Zpot, zeta potential.
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the diffusion of FB from the PBS solution and Ocufen® was 
faster and was completed in 120 minutes. The NPs showed 
a biphasic pattern, ie, an immediate release (“burst effect”) 
followed by a slower release proﬁle. The initial fast release 
was attributed to the fraction of the drug that is adsorbed or 
weakly bound to the NP surface. After this initial phase, the 
drug exhibited delayed release.
As can be observed in Figure 3A, release of the drug from 
PLGA NPs was signiﬁcantly faster than from NPs with con-
jugated peptides. Release of the drug was signiﬁcantly slower 
for PLGA-NPs-PEG-HIV-Tat than from PLGA-NPs-PEG-
POD (56.5% and 83.3%, respectively) after 120 minutes of 
follow-up. The more delayed release of FB from HIV-Tat 
(compared to POD) resulted in a maximum release proﬁle 
of 90% over the whole study period (8 hours). This might 
be due to the greater amount of HIV-Tat peptide per unit 
of NP surface area, compared to POD, as described above. 
Figure 3B shows the release proﬁles of FB from PLGA-PEG 
NPs, PLGA-PEG® NPs, and PLGA-PEG-peptide NPs. No 
signiﬁcant differences were observed between PLGA-PEG 
NPs and PLGA-PEG® NPs; and release of the drug was faster 
than observed from PLGA-PEG-peptide NPs, in agreement 
with previous results.41 In contrast to the results obtained 
for the PLGA-NPs-PEG-peptide formulations, the release 
of the drug was slower for PLGA-PEG-POD NPs than for 
PLGA-PEG-HIV-Tat NPs (46.1% and 80.9%, respectively). 
It seems that the presence of POD inside the polymeric 
matrix produced a more retarded release of the drug than 
for the other NP formulations, probably due to the greater 
FB-POD interaction, as observed in the EE results shown 
in Table 2. This interaction might introduce resistance to 
the diffusional release of the drug, thereby yielding a more 
sustained release of FB.
The development of advanced drug delivery systems 
relies on the judicious and careful selection of components, 
conﬁgurations, and geometries, which can be facilitated 
through mathematical modeling of controlled release sys-
tems. Therefore, data obtained from the in vitro release stud-
ies were modeled by the Korsmeyer–Peppas kinetics equation 
to establish the mechanism of FB release from PLGA-NPs-
PEG-peptide and PLGA-PEG-peptide NPs. The diffusion 
exponent (n) and the release rate constant (k) obtained are 
indicated in Table S1. All the NPs had n values in the range 
0.47–0.74; with a coefﬁcient, r2, of between 0.948 and 0.989. 
These results indicated that the release of FB from these 
systems follows a non-Fickian diffusion mechanism, which 
is probably governed by a combination of drug diffusion and 
polymer chain relaxation during polymer swelling.60
As already demonstrated, the PLGA-PEG-peptide NPs 
derived from the modiﬁed polymer showed the best results; 
speciﬁcally, PLGA-PEG-POD NPs were the smallest NPs, 
and they exhibited both the highest EE and the most sustained 
release. So, these NPs should be considered as candidates for 
drug delivery into intraocular tissues, and they were selected 
for further biological studies.
ex vivo clsM study of the interaction 
of Plga-Peg-peptide NPs with the 
corneal epithelium
In order to evaluate the NPs as delivery carrier to uptake 
the corneal epithelium, the peptides were labeled with Rho 
and were used to prepare fluorescent NPs. The MALDI-
TOF spectra revealed the presence of the labeled peptides 
and, furthermore, revealed the absence of unlabeled peptide 
molecules (Figure S4). The degree of peptide labeling was 
determined by measuring the absorbance of free and labeled 
Figure 3 In vitro release profiles of FB from (A) Plga-NPs-Peg-peptide, (B) Plga-Peg NPs, and Plga-Peg-peptide NPs.
Abbreviations: FB, flurbiprofen; HIV-Tat, human immunodeficiency virus transactivator; NPs, nanoparticles; PEG, polyethyleneglycol; Peg®, resomer® rgP type d5055; 
Plga, poly(lactic-co-glycolic acid); POD, peptide for ocular delivery.
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peptides, yielding 0.003 mol Rho/mol POD and 0.04 mol 
Rho/HIV-Tat. Then, PLGA-PEG-Rho-peptide NPs were 
produced, and the results showed that the PLGA-PEG-Rho-
POD and PLGA-PEG-Rho-HIV-Tat NPs contained similar 
concentrations of labeled peptide (approximately 0.25 µM). 
The physicochemical parameters (Table S2) were similar 
to those obtained for the unlabeled NPs. An optimal size 
for ocular delivery (100 nm) and the positive charge was 
maintained. Fluorescence microscopy was used to visualize 
the labeled NPs (Figure S5). The fluorescence images were 
also similar for both NPs and illustrate that a homogeneous 
particle size distribution was obtained.
Cornea is the major route of anterior drug absorption. 
There are three corneal layers, namely epithelium, stroma, 
and endothelium, and all of them have a distinct role in 
transcorneal drug permeability. The corneal epithelium is 
the major limiting barrier in transcorneal drug absorption. 
CLSM images showed the corneal epithelium of the rabbit 
once it had been exposed to PLGA-PEG-Rho-POD NPs and 
PLGA-PEG-Rho-HIV-Tat NPs (Figure 4). Although both 
peptides increase the interaction with the mucin (data not 
shown), the ex vivo study by CLSM show that PLGA-PEG-
POD NPs have a better interaction than PLGA-PEG-HIV-Tat 
NPs with epithelial cells. More fluorescent spots can be seen 
in the images that correspond to the NPs containing POD than 
those containing HIV-Tat. This suggests that the PLGA-PEG-
Rho-POD NPs interact more with the corneal epithelium. 
As previously reported in the literature, the penetration rate 
was dependent on the coating composition.61 Kompella et al62 
demonstrated that corneal epithelial uptake of 20 nm NPs can 
be elevated from approximately 2%–16% by surface coating 
or functionalizing NPs.
Hoechst dyes and wheat germ agglutinin were used to 
distinguish the boundaries of the nucleus and the cell mem-
brane, respectively. We observed that the fluorescent spots 
were mainly distributed around the nucleus of the cells, indi-
cating that the NPs penetrated the corneal epithelium through 
a transcellular pathway. These results are in agreement with 
those reported by other authors for PLGA-PEG,41 poly-ε-
caprolactone,63 and poly(alkyl cyanoacrylate)64 NPs.
Figure 4 clsM images of a cross-section of (A) corneal epithelium at depth of 10 µm, (B) pretreated with Plga-Peg-hIV-Tat-rho NPs, (C) pretreated with Plga-Peg-
POD-rho NPs, (D) their corresponding phase contrast with nucleus, and (E) cell membranes.
Abbreviations: CLSM, confocal laser scanning microscopy; HIV-Tat, human immunodeficiency virus transactivator; NPs, nanoparticles; PEG, polyethyleneglycol; PLGA, 
poly(lactic-co-glycolic acid); POD, peptide for ocular delivery; rho, 5(6)-carboxytetramethylrhodamine.
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In vitro cytotoxicity of Plga-Peg-
peptide NPs
To assess the cellular cytotoxicity of the NPs, HeLa and 
HepG2 cell lines were used. Cytotoxic activity was evalu-
ated at concentrations ranging from 0.1 to 25 mg/mL. Fol-
lowing 24 hours of exposition to the NPs, cell viability was 
assessed using the MTT assay. The results were plotted onto 
a ﬁtted curve to obtain median lethal dose (LD
50
) values 
(NP concentration s at which cell viability is 50%). PLGA-
PEG NPs without FB were used as a control. While the 
FB solution showed higher cytotoxicity, the experimental 
LD
50
 values for PLGA-PEG-HIV-Tat NPs were 10.8 mg/
mL in HepG2 cells and 8.4 mg/mL in HeLa cells, whereas 
the PLGA-PEG-POD NPs rendered values of 4.4 mg/mL 
and 3.9 mg/mL, respectively (Figure 5). These results cor-
respond to approximately 200–300 mg/kg of body weight 
in an adult human, suggesting low in vitro cytotoxicity, as 
this would be a much higher intravenous dose than required 
for in vivo drug delivery.65 Representative photographs of 
HeLa and HepG2 cells are shown, with no NPs added (left 
column), incubated with NPs at LD
50
 values (center col-
umn), and incubated with NPs at lethal dose values (right 
column) (Figure 5C).
Ocular tolerance assays
For an ocular instillation drug delivery system, it is 
extremely important to test ocular tolerability. In accor-
dance with the concept of the 3Rs (reduction, reﬁnement 
and, replacement), several techniques are available to 
reduce and replace animal testing. In vitro screening 
serves as a preliminary method to assess possible risk in 
animal studies. Since a single in vitro test cannot mimic 
complete in vivo behavior, eg, the entire systemic mecha-
nism including inflammation, penetration/permeability, 
and tolerance, the assays were also carried out on male 
albino rabbits.
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Figure 5 cytotoxicity of Plga-Peg-peptide NPs on (A) hepg2 and (B) hela cells lines using the MTT assay, and photographs of (C) hepg2 and hela cells incubated 
with NPs to lD50 and lD100 concentrations.
Abbreviations: hIV-Tat, human immunodeficiency virus transactivator; lD50, median lethal dose; lD100, lethal dose; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium; NPs, nanoparticles; Peg, polyethyleneglycol; Plga, poly(lactic-co-glycolic acid); POD, peptide for ocular delivery.
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In vitro heT-caM
The CAM is a noninnervated complete tissue containing 
arteries, veins, and capillaries, and it is technically easy to 
study. It responds to injury via an inflammatory process 
similar to that observed in the conjunctival tissue of a rabbit 
eye. The well-developed CAM vascularization provides an 
ideal model for ocular irritation studies.
The HET-CAM, a suitable alternative to animal testing, is 
based on direct application onto the CAM and the subsequent 
reactions, such as hemorrhage, intravasal coagulation, or lysis 
of blood vessels, which are microscopically assessed along 
a time-course.47 These irritancy effects may occur within 
5 minutes of mucosal administration of the sample onto the 
HET-CAM, according to the INVITTOX protocol.66
Ocular tolerance assays for free FB in PBS showed slight 
irritancy. In contrast, when the different NP formulations 
developed in this work were added, no signs of ocular irri-
tancy were detected within 5 minutes; the irritancy index was 
zero (Figure S6). With respect to the effect of particle size on 
ocular irritancy, as described by Schoenwald and Stewart,54 
only particles of 20 µm mean diameter induced irritation. 
Thus, the FB-loaded NPs seem to be suitable systems for 
ocular administration, and the observed long-term changes 
in their average size do not reach the critical range.
In vivo Draize test
Topical application of the NPs to rabbit eyes showed 
no signs of irritation in the cornea, conjunctiva, or iris 
NPs SA 
0
30 60 120 180 210
5
10
15
20
25
SA Ocufen® PLGA-PEG-NPs PLGA-PEG-POD-NPs PLGA-PEG-HIV-Tat-NPs
*
*
**
***
*
***
***
** *
*
*** *** ***
***
**
**
Time (minutes)
O
cu
la
r 
in
fla
m
m
at
io
n 
sc
or
e
A
0
SA NPs 
0 30 60 90 120 150 180 210
5
0
10
15
20
25
SA Ocufen® PLGA-PEG PLGA-PEG-POD PLGA-PEG-HIV-Tat
* **
***
**
***
***
****** ***
***
***
***
$$
******
***
***
$$
******
***
***
***
***
***
***
$$
$
$$$
$$$
Time (minutes)
O
cu
la
r 
in
fla
m
at
io
n 
sc
or
e
B
Figure 6 Comparison of anti-inflammatory efficacy of PLGA-PEG NPs, PLGA-PEG-peptide NPs, and Ocufen® in the (A) treatment and (B) prevention of ocular inflammation 
induced by sa in the rabbit eye.
Notes: Values are expressed as mean ± sD; *P0.05, **P0.01, and ***P0.001 significantly lower than the inflammatory effect induced by SA; $P0.05, $$P0.01, and 
$$$P0.001 significantly lower than anti-inflammatory efficacy of Ocufen®.
Abbreviations: HIV-Tat, human immunodeficiency virus transactivator; NPs, nanoparticles; PEG, polyethyleneglycol; PLGA, poly(lactic-co-glycolic acid); POD, peptide for 
ocular delivery; sa, sodium arachidonate; sD, standard deviation.
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(MTS =0) (Figure S7). These results are in accordance 
with those obtained in the HET-CAM test.
Anti-inflammatory efficacy assay
Two studies were performed to determine the anti-inflammatory 
efﬁcacy of the NPs in order to probe their usefulness for pre-
venting and treating inflammation during cataract surgery.
Conjunctival inflammation with signiﬁcant hyperemia 
was induced by SA, peaking at 30 minutes. In general, NPs 
containing FB (Table 2) and Ocufen® signiﬁcantly decreased 
the ocular inflammation, showing no signiﬁcant differ-
ences among them (Figure 6). Only PLGA-PEG-POD NPs 
exhibited better anti-inflammatory response than the other 
formulations at 120 minutes in the prevention of inflam-
mation (Figure 6B), and the SA-induced inflammation was 
inhibited 210 minutes after SA instillation. These results are 
in accordance with those obtained in the ex vivo study by 
CLSM, where it was demonstrated that PLGA-PEG-POD 
NPs had a better interaction than PLGA-PEG-HIV-Tat 
NPs with epithelial cells. Thus, the in vivo results might 
be explained on the basis of the prolonged retention in the 
precorneal area and also in the uptake/internalization into 
the corneal epithelium.
As can be observed in Figure 6A, in the case of treatment, 
no improvement was achieved using PLGA-PEG-POD-NPs, 
while a better anti-inflammatory efﬁcacy was observed in the 
prevention of inflammation (Figure 6B and Figure S8). These 
results could be related to the different absorption of NPs in 
healthy and inflamed tissues. The instillation of SA prior to 
administration of NPs led to enhanced lacrimation and thus 
increasing precorneal loss and clearance of NPs. Our results 
showed that PLGA-PEG-POD NPs enhance the ocular tissue 
residence time and the anti-inflammatory efﬁcacy of FB.
Conclusion
In this study, we proposed PLGA-PEG NPs modiﬁed with 
POD or HIV-Tat as an effective ocular drug delivery sys-
tem to reduce inflammation after cataract surgery. Of the 
formulations devised, PLGA-PEG-POD NPs showed the 
best results: uniformly spherical shape with a particle size 
of 103.7±0.3 nm. Their morphology was conﬁrmed by SEM 
and fluorescence microscopy. Moreover, their positive Z
pot
 
(18.6±1.5 mV) promotes ocular mucoadhesion. Furthermore, 
these NPs present higher EE and more sustained release of 
FB, the anti-inflammatory drug studied. PLGA-PEG-POD 
NPs enhanced the delivery of drugs to the corneal epithelium 
and represent an effective system for increasing the bioavail-
ability of FB. The NPs were tolerated well by human cell 
line models (HeLa and HepG2) and did not induce any sign 
of irritation during ocular tolerance studies (either in vitro 
or in vivo). Their anti-inflammatory efﬁcacy suggests that 
PLGA-PEG-POD NPs may be employed to prevent ocular 
inflammatory reactions in which the SA cascade is activated. 
These results indicated that PLGA-PEG-POD NPs could 
offer an effective ocular drug delivery system that would 
facilitate permeation of FB via topical application.
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Figure S1 MalDI-TOF mass spectra of (A) POD, (C) hIV-Tat peptides, and (B and D) the conjugation with maleimide-Peg-amine.
Abbreviations: HIV-Tat, human immunodeficiency virus transactivator; MALDI-TOF, matrix-assisted laser desorption/ionization-time of flight; PEG, polyethyleneglycol; 
POD, peptide for ocular delivery.
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Figure S2 1h-NMr spectra of (A) Plga-Peg-metoxi and (B) Plga-Peg-maleimide copolymers.
Abbreviations: 1h-NMr, proton nuclear magnetic resonance; Peg, polyethyleneglycol; Plga, poly(lactic-co-glycolic acid).
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Table S1 Release kinetics obtained after fitting FB release data from PLGA-NPs-PEG-peptide and PLGA-PEG-peptide NPs into 
Korsmeyer–Peppas model
NPs composition Korsmeyer–Peppas model* Transport mechanism
r2 k ± SD (h-n) n ± SD
NPs obtained following the scheme indicated in Figure 1A
Plga-NPs-Peg-POD 0.948 7.23±1.32 0.47±0.02 Non-Fickian or anomalous diffusion
Plga-NPs-Peg-hIV-Tat 0.974 2.67±0.07 0.63±0.01 Non-Fickian or anomalous diffusion
NPs obtained following the scheme indicated in Figure 1B
Plga-Peg-POD NPs 0.989 2.71±1.48 0.60±0.07 Non-Fickian or anomalous diffusion
Plga-Peg-hIV-Tat NPs 0.967 2.56±0.20 0.74±0.11 Non-Fickian or anomalous diffusion
Notes: Values are expressed as mean ± sD; n=3; *non-significant differences were observed between POD and HIV-Tat NPs obtained following schemes of Figure 1A and B.
Abbreviations: FB, flurbiprofen; HIV-Tat, human immunodeficiency virus transactivator; k, the release rate constant; n, the diffusion exponent; NPs, nanoparticles; Peg, 
polyethyleneglycol; Plga, poly(lactic-co-glycolic acid); POD, peptide for ocular delivery; sD, standard deviation.
Figure S3 scanning electron microscopy analysis of Plga-Peg-POD NPs.
Abbreviations: NPs, nanoparticles; Peg, polyethyleneglycol; Plga, poly(lactic-co-glycolic acid); POD, peptide for ocular delivery.
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Table S2 Physicochemical properties of Plga-Peg-peptide-rho NPs
NPs composition Size ± SD (nm) PI ± SD Zpot ± SD (mV)
Plga-Peg-POD-rho NPs 87.2±0.3 0.112±0.041 22.6±2.7
Plga-Peg-hIV-Tat-rho NPs 99.7±1.2 0.083±0.028 15.8±0.8
Abbreviations: HIV-Tat, human immunodeficiency virus transactivator; NPs, nanoparticles; PEG, polyethyleneglycol; PI, polydispersity index; PLGA, poly(lactic-co-glycolic 
acid); POD, peptide for ocular delivery; rho, 5(6)-carboxytetramethylrhodamine; sD, standard deviation; Zpot, zeta potential.
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Figure S4 MalDI-TOF spectra of (A) rho-POD and (B) rho-hIV-Tat peptides.
Abbreviations: HIV-Tat, human immunodeficiency virus transactivator; MALDI-TOF, matrix-assisted laser desorption/ionization-time of flight; Rho, 5(6)-carboxytetram-
ethylrhodamine; POD, peptide for ocular delivery.
A B
Figure S5 Fluorescence microscopy images of (A) Plga-Peg-peptide-rho NPs and (B) green emission of all scanned NPs.
Abbreviations: NPs, nanoparticles; Peg, polyethyleneglycol; Plga, poly(lactic-co-glycolic acid); rho, 5(6)-carboxytetramethylrhodamine.
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Figure S6 Photographs of caM 5 minutes after the addition of NPs containing FB: (A) Plga NPs, (B) Plga-Peg NPs, (C) Plga-Peg-POD NPs, (D) Plga-Peg-hIV-Tat 
NPs, and (E) positive control (0.1 M sodium hydroxide).
Abbreviations: CAM, chorioallantoic membrane; FB, flurbiprofen; HIV-Tat, human immunodeficiency virus transactivator; NPs, nanoparticles; PEG, polyethyleneglycol; 
Plga, poly(lactic-co-glycolic acid); POD, peptide for ocular delivery.
Figure S7 Draize test after instillation of Plga-Peg-POD NPs (A) and inflammation induced by SA (B).
Abbreviations: NPs, nanoparticles; Peg, polyethyleneglycol; Plga, poly(lactic-co-glycolic acid); POD, peptide for ocular delivery; sa, sodium arachidonate.
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Figure S8 Anti-inflammatory effect of PLGA-PEG-POD NPs in the prevention of ocular inflammation induced by SA.
Note: The images were taken 30 minutes after inducing inflammation.
Abbreviations: NPs, nanoparticles; Peg, polyethyleneglycol; Plga, poly(lactic-co-glycolic acid); POD, peptide for ocular delivery; sa, sodium arachidonate.
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